Treatment of Malignant Pleural Effusion with ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Trial Profile

Treatment of Malignant Pleural Effusion with ZD6474, a Novel Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth factor Receptor (EGFR) Tyrosine Kinase Inhibitor.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Mar 2016

At a glance

  • Drugs Vandetanib (Primary)
  • Indications Malignant pleural effusion
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 22 Jun 2014 Status changed from active, no longer recruiting to discontinued, as per M.D. Anderson Cancer Center record.
    • 23 Sep 2013 Planned end date changed from 1 Oct 2014 to 1 Oct 2015 as reported by ClinicalTrials.gov.
    • 21 Sep 2012 Planned end date changed from 1 Oct 2012 to 1 Oct 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top